The randomised, double-blind, placebo-controlled pilot study will evaluate if the application of magnetic fields produced by Pico-Tesla’s patented Resonator system will be effective as an adjunctive therapy to oral medications, in reducing Alzheimer’s disease symptoms.

Pico-Tesla’s Magneceutical Therapy uses the Resonator, which generates extremely low-level electromagnetic field (EMF), to reduce the symptoms of Alzheimer’s disease.

The device is currently in clinical trials to evaluate its effectiveness in reducing symptoms of various diseases such as atrial fibrillation, Parkinson’s disease, fibromyalgia and osteoarthritis.